Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04933552 · ClinicalTrials.gov registry record
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent
A clinical trial of Multiple Sclerosis, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- 867
- Enrollment target
- 1
- Study location
NCT04933552: Recruiting study of Multiple Sclerosis, sponsored by Novartis Pharmaceuticals.
NCT04933552 is a study of Multiple Sclerosis that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 867 participants, above the 582-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (49% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04933552, a study of Multiple Sclerosis, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- 867 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will utilize a prospective, observational, exposure cohort design to examine pregnancy and infant outcomes in women and infants who are exposed to siponimod during pregnancy to treat MS.
Primary Outcome
A major structural defect is defined as a defect that has either cosmetic or functional significance to the child (e.g., a cleft lip).
Conditions Studied
Interventions
- OTHER Siponimod
Study Locations (1)
California
- Novartis Investigative Site - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 867 participants |
| Start Date | 2021-12-15 |
| Est. Completion | 2032-05-31 |
What NCT04933552 shows while recruiting
NCT04933552 is an observational study that tracks outcomes without assigning an intervention. The registered 867 participants enrollment target is mid-sized for trials with a published cap, above the 582-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (49% higher).
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Siponimod is the first listed.
NCT04933552 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04933552 about?
NCT04933552 is a clinical study titled "Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent". This study will utilize a prospective, observational, exposure cohort design to examine pregnancy and infant outcomes in women and infants who are exposed to siponimod during pregnancy to treat MS.
What is the current status of trial NCT04933552?
This trial is currently recruiting. The enrollment target is 867 participants. The study started on 2021-12-15. Estimated completion is 2032-05-31.
What conditions does trial NCT04933552 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT04933552?
The interventions under investigation include: Siponimod (OTHER).
Who is sponsoring clinical trial NCT04933552?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04933552 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04933552's enrollment target sits among peer trials
867 33rd of 315 higher than 283 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
RECRUITING
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06077760 · 868 participants · Phase 3
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
- NCT06822790 · 869 participants · Phase 3
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
- NCT05369052 · 865 participants · Phase 3
Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)
- NCT04097145 · 870 participants · NA
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI